title: Ifosfamide in the treatment of non-small cell lung cancer.
abstract: Thirteen single-agent and 23 combination chemotherapeutic regimen trials using ifosfamide involving 1,326 evaluable patients with non-small cell lung cancer were reviewed. From these studies, several conclusions can be drawn: (1) ifosfamide as a single agent shows response rates greater than 20%; (2) in combination with cisplatin, with or without a third drug, ifosfamide induces response rates of 38%; however, survival is not increased significantly; (3) other combinations with ifosfamide have a response rate greater than 35%; and (4) ifosfamide warrants continued evaluation and testing in combination with other effective agents.
authors.affiliation: Johns Hopkins Oncology Center, Baltimore, MD 21205.
authors.forename: D S
authors.initials: DS
authors.lastname: Ettinger
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003131:Combined Modality Therapy; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy*; D012074:Remission Induction
chemical_list: D007069:Ifosfamide